(19)
(11) EP 1 320 379 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.06.2010 Bulletin 2010/22

(45) Mention of the grant of the patent:
28.04.2010 Bulletin 2010/17

(21) Application number: 01965468.0

(22) Date of filing: 13.09.2001
(51) International Patent Classification (IPC): 
A61K 39/015(2006.01)
A61K 39/04(2006.01)
A61P 31/04(2006.01)
A61P 33/06(2006.01)
 A61K 39/00(2006.01)
A61P 31/06(2006.01)
A61P 31/12(2006.01)
(86) International application number:
PCT/GB2001/004116
(87) International publication number:
WO 2002/024224 (28.03.2002 Gazette 2002/12)

(54)

USE OF REPLICATION-DEFICIENT POXVIRUS VECTOR TO BOOST CD4+ T CELL IMMUNE RESPONSE TO ANTIGEN

VERWENDUNG EINES REPLIKATIONDEFIZIENTEN POCKENVIRUSVEKTORS ZUR ERHÖHUNG DER CD4+ T-ZELL-IMMUNANTWORT GEGEN ANTIGEN

UTILISATION D'UN VECTEUR DE POXVIRUS DEFICIENT POUR LA REPLICATION POUR STIMULERLA REPONSE IMMUNITAIRE DES LYMPHOCYTES T CD4+ CONTRE L'ANTIGENE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 21.09.2000 GB 0023203

(43) Date of publication of application:
25.06.2003 Bulletin 2003/26

(73) Proprietor: Oxford Biomedica (UK) Ltd
Robert Robinson Avenue Oxford Science Park Oxford, OX4 4GA (GB)

(72) Inventors:
  • HILL, Adrian, V. S.
    Oxford OX3 9DL (GB)
  • McSHANE, Helen
    Oxford OX2 7RF (GB)
  • GILBERT, Sarah
    Horspath, Oxford O X33 1SD (GB)
  • REECE, William
    Oxford OX4 2NY (GB)
  • SCHNEIDER, Joerg
    Oxford OX3 8BT (GB)

(74) Representative: Goodfellow, Hugh Robin 
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA
London WC1A 2RA (GB)


(56) References cited: : 
WO-A-98/56919
   
  • RAMSHAW I A ET AL: "The prime-boost strategy: exciting prospects for improved vaccination" IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 4, April 2000 (2000-04), pages 163-165, XP004194963 ISSN: 0167-5699
  • PLEBANSKI MAGDALENA ET AL: "Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use." EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 12, December 1998 (1998-12), pages 4345-4355, XP002192944 ISSN: 0014-2980
  • JOHNSON R P ET AL: "INDUCTION OF A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RESTRICED CYTOTOXIC T-LYMPHOCYTE RESPONSE TO A HIGHLY CONSERVED REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120 IN SERONEGATIVE HUMANS IMMUNIZED WITH A CANDIDATE HIV-1 VACCINE" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 5, May 1994 (1994-05), pages 3145-3153, XP001027055 ISSN: 0022-538X
  • SCHNEIDER J ET AL: "ENHANCED IMMUNOGENICITY FOR CD8+ T CELL INDUCTION AND COMPLETE PROTECTIVE EFFICACY OF MALARIA DNA VACCINATION BY BOOSTING WITH MODIEFIED VACCINIA VIRUS ANKARA" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 4, April 1998 (1998-04), pages 397-402, XP000739989 ISSN: 1078-8956
  • DENIS O ET AL: "Vaccination with plasmid DNA encoding Mycobacterial Antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 66, no. 4, April 1998 (1998-04), pages 1527-1533, XP002173898 ISSN: 0019-9567
  • MCSHANE HELEN ET AL: "Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis." INFECTION AND IMMUNITY, vol. 69, no. 2, February 2001 (2001-02), pages 681-686, XP002192945 ISSN: 0019-9567
  • A. LALVANI ET AL.: "Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis" PNAS USA, vol. 95, 1998, pages 270-275,
  • A. LALVANI & A.V.S. HILL: "Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design" vol. 95, 1998, pages 531-538,
  • S.M. SMITH ET AL.: "Characterization of human Mycobacterium bovis bacille Calmette-Guerin-reactive CD8+ T cells" vol. 67, no. 10, 1999, pages 5223-5230,
  • A.A. PATHAN ET AL.: "High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 30, no. 9, September 2000 (2000-09), pages 2713-2721,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).